Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Max Nobis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1861-1390; OpenAlex author ID A5007413731. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 13

  1. Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02347-y↗
  2. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  3. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  4. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  5. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  6. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  7. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  8. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  9. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  10. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  11. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  12. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  13. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-4545↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Robatel · 1 shared paper, 2026 · strength 0.25
  2. Mirjam Schenk · 1 shared paper, 2026 · strength 0.25
  3. Martin Wartenberg · 1 shared paper, 2026 · strength 0.25
  4. Ulf Kessler · 1 shared paper, 2026 · strength 0.25
  5. Yingxiao Wang · 3 shared papers, 2013–2021 · strength 0.16
  6. Jennifer P. Morton · 3 shared papers, 2013–2021 · strength 0.16
  7. Owen James Sansom · 3 shared papers, 2013–2021 · strength 0.16
  8. Paul Timpson · 3 shared papers, 2013–2021 · strength 0.16
  9. Claire Vennin · 2 shared papers, 2018–2021 · strength 0.14
  10. Kendelle Joan Murphy · 2 shared papers, 2018–2021 · strength 0.14
  11. Marina Pajic · 2 shared papers, 2018–2021 · strength 0.14
  12. David Herrmann · 2 shared papers, 2018–2021 · strength 0.14
  13. James R. W. Conway · 2 shared papers, 2018–2021 · strength 0.14
  14. Ashleigh Parkin · 1 shared paper, 2021 · strength 0.08
  15. Michael Tayao · 1 shared paper, 2021 · strength 0.08
  16. Jaswinder Singh Samra · 1 shared paper, 2021 · strength 0.08
  17. Angela S. Y. Chou · 1 shared paper, 2021 · strength 0.08
  18. Shona Ritchie · 1 shared paper, 2021 · strength 0.08
  19. Thomas R. Cox · 1 shared paper, 2021 · strength 0.08
  20. Amber L. Johns · 1 shared paper, 2021 · strength 0.08
  21. Cecilia R. Chambers · 1 shared paper, 2021 · strength 0.08
  22. Roger J. Daly · 1 shared paper, 2021 · strength 0.08
  23. Sean Michael Grimmond · 1 shared paper, 2021 · strength 0.08
  24. Anthony James Gill · 1 shared paper, 2021 · strength 0.08
  25. Brooke Pereira · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.